Potent, selective non-thiazolidinedione PPARγ partial agonist (EC50 = 57 nM); produces ~25% maximum efficacy. Antagonizes full agonist activity by ~60% (IC50 ~ 285 nM). Displays no activity at PPARα or PPARδ receptors. Produces altered receptor conformation, and regulates adipocyte development and gene expression, in a differential manner to full PPARγ agonists. Modulates metabolism and insulin sensitivity without causing cardiac hypertrophy in mice in vivo.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 428.33. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.33 mL||11.67 mL||23.35 mL|
|5 mM||0.47 mL||2.33 mL||4.67 mL|
|10 mM||0.23 mL||1.17 mL||2.33 mL|
|50 mM||0.05 mL||0.23 mL||0.47 mL|
References are publications that support the products' biological activity.
Berger et al (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Mol.Endocrinol. 17 662 PMID: 12554792
If you know of a relevant reference for nTZDpa, please let us know.
View Related Products by Product Action
Keywords: nTZDpa, supplier, Potent, selective, PPARγ, PPARgamma, partial, agonists, Peroxisome, Proliferator-activating, Receptors, PPARgamma, Receptors, PPARgamma, Receptors, Tocris Bioscience
Citations for nTZDpa
Citations are publications that use Tocris products.
Currently there are no citations for nTZDpa. Do you know of a great paper that uses nTZDpa from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)